DFTX · NASDAQ
Definium Therapeutics (DFTX) Stock Price & Fundamentals
Definium Therapeutics (DFTX) closed at $843.81 on Oct 9, 2026, down 0.43% from the previous close of $847.48.
Share price, past year
1Y +31.07%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $843.81 |
| Sep 30, 2026 | $847.11 |
| Aug 31, 2026 | $752.81 |
| Jul 31, 2026 | $749.33 |
| Jun 30, 2026 | $731.56 |
| May 29, 2026 | $742.34 |
| Apr 30, 2026 | $696.16 |
| Mar 31, 2026 | $692.65 |
| Feb 27, 2026 | $684.02 |
| Jan 30, 2026 | $690.50 |
| Dec 31, 2025 | $681.74 |
| Nov 28, 2025 | $657.02 |
| Oct 31, 2025 | $636.84 |
Key statistics
- Market cap
- $113.38B
- EPS (TTM)
- −$3.36
- Net income (TTM)
- −$353.79M
- Shares outstanding
- 134.4M
- 52-week range
- $625.85 – $855.89
Definium Therapeutics's market cap is $113.38B, based on a share price of $843.81 and 134.4M shares outstanding as of Jun 30, 2026.
Financials
Definium Therapeutics's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Definium Therapeutics reported a net loss of $183.79M in fiscal 2025.
Company profile
- Name
- Definium Therapeutics, Inc.
- Ticker
- DFTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Medicinal Chemicals & Botanical Products
- Headquarters
- One World Trade Center, Suite 8500, New York, NY 10007
- Incorporated in
- A1
- Fiscal year ends
- December
- SEC CIK
- 0001813814
Recent SEC filings
- Sep 14, 2026
- Sep 8, 2026
- Aug 12, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 24, 2026
- Jun 22, 2026
- Jun 12, 2026
Frequently asked questions
What is Definium Therapeutics's stock price?
Definium Therapeutics (DFTX) closed at $843.81 on Oct 9, 2026, down 0.43% from the previous close of $847.48.
What is Definium Therapeutics's market cap?
Definium Therapeutics's market cap is $113.38B, based on a share price of $843.81 and 134.4M shares outstanding as of Jun 30, 2026.
Does Definium Therapeutics pay a dividend?
Definium Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Definium Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures